Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61K - Preparations for medical, dental, or toilet purposes › A61K 31 - Medicinal preparations containing organic active ingredients
Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912)
11/2010
11/25/2010US20100297266 Preparations and methods for textile and or fiber surface finishing, surface finished articles prepared thereby, and uses therefor
11/25/2010US20100297264 Bowel purgative and uses thereof
11/25/2010US20100297263 Colon cleansing compositions and methods
11/25/2010US20100297262 Pharmaceutically active compositions comprising oxidative stress modulators (osm), new chemical entities, compositions and uses
11/25/2010US20100297256 Methods and compositions for inhibiting integrins using tellurium-containing compounds
11/25/2010US20100297252 Nanoparticulate meloxicam formulations
11/25/2010US20100297251 Encapsulated particles for enteric release
11/25/2010US20100297250 Alkynes and methods of reacting alkynes with 1,3-dipole-functional compounds
11/25/2010US20100297248 Encapsulated particles for amorphous stability enhancement
11/25/2010US20100297247 Aqueous-Core Lipid Nanocapsules for Encapsulating Hydrophilic and/or Lipophilic Molecules
11/25/2010US20100297244 Nanodispersion
11/25/2010US20100297243 Prion free nanoparticle compositions and methods of making thereof
11/25/2010US20100297242 Ldl-like cationic nanoparticles for deliverying nucleic acid gene, method for preparing thereof and method for deliverying nucleic acid gene using the same
11/25/2010US20100297241 Amorphous Fesoterodine Fumarate
11/25/2010US20100297240 1- [2- (2,4-dimethylphenylsulfanyl)-phenyl] piperazine as a compound with combined serotonin reuptake, 5-ht3 and 5-ht1a activity for the treatment of cognitive impairment
11/25/2010US20100297237 Nanoparticles comprising a non-ionizable polymer and an amine-functionalized methacrylate copolymer
11/25/2010US20100297235 Vascular puncture closure systems, devices, and methods using biocompatible synthetic hydrogel compositions
11/25/2010US20100297232 Ondansetron film compositions
11/25/2010US20100297229 Tapentadol compositions
11/25/2010US20100297227 Pharmaceutical composition comprising at least one active agent and a binder, which swells in an acidic media
11/25/2010US20100297226 Multiple unit pharmaceutical formulation
11/25/2010US20100297225 Sustained-release pharmaceutical formulation containing an antimuscarinic agent and a wetting agent as well as a process for the preparation thereof
11/25/2010US20100297224 NSAID Dose Unit Formulations with H2-Receptor Antagonists and Methods of Use
11/25/2010US20100297221 pharmaceutical composition of tacrolimus
11/25/2010US20100297220 Pharmaceutical Formulation And Method For Treating Acid-Caused Gastrointestinal Disorders
11/25/2010US20100297216 Method for administration of pegylated liposomal doxorubicin
11/25/2010US20100297215 Compositions and methods for protecting cells during cancer chemotherapy and radiotherapy
11/25/2010US20100297205 Patch for the expulsion of insect poison from the skin after stings from membranous insects (hymenoptera)
11/25/2010US20100297200 Use of nitric oxide to enhance the efficacy of silver and other topical wound care agents
11/25/2010US20100297199 Nanoemulsion of resveratrol-phospholipid complex and method for preparing the same and applications thereof
11/25/2010US20100297196 Cytokine modulators using cyclic glycerides of essential polyunsaturated fatty acids
11/25/2010US20100297195 Controlled release lamotrigine formulations
11/25/2010US20100297194 Formulation for oral administration of apoptosis promoter
11/25/2010US20100297181 AMPA Receptor Antagonists for Epilepsy, Mental Disorders or Deficits in Sensory Organ
11/25/2010US20100297165 Immunostimulatory combinations of tlr ligands and methods of use
11/25/2010US20100297156 Analogues of phosphatidylinositol mannosides
11/25/2010US20100297153 Binding molecules for treatment and detection of cancer
11/25/2010US20100297150 Disease treatment via antimicrobial peptide inhibitors
11/25/2010US20100297149 Compositions and methods comprising histidyl-trna synthetase splice variants having non-canonical biological activities
11/25/2010US20100297148 Cd38 modulated chemotaxis
11/25/2010US20100297147 Compositions and methods for modulating tlr14 activity
11/25/2010US20100297145 Apoptosis promoter, cell proliferation inhibitor, prophylactic/therapeutic agent for cancer, screening method for the promoter, inhibitor or agent
11/25/2010US20100297142 Methods of using (+)-1,4-dihydro-7-[(3s,4s)-3-methoxy-4-(methylamino)-1-pyrrolidinyl]-4-oxo-1-(2-thiazolyl)-1,8-naphthyridine-3-carboxylic acid in combination therapy
11/25/2010US20100297136 Gastric and Prostate Cancer Associated Antigens
11/25/2010US20100297131 Binding domain of plasmodium reticulocyte binding proteins
11/25/2010US20100297128 Gamma secretase modulators
11/25/2010US20100297127 Use of il-27 antagonists to treat lupus
11/25/2010US20100297124 Induced internalization of surface receptors
11/25/2010US20100297123 Combination therapy to inhibit t cell effector function
11/25/2010US20100297121 Methods for Treating Pressure Induced Optic Neuropathy, Preventing Neuronal Degeneration and Promoting Neuronal Cell Survival Via Administration of LINGO-1 Antagonists and TrkB Agonists
11/25/2010US20100297118 Therapeutic Cancer Treatments
11/25/2010US20100297113 Quinone derivatives, pharmaceutical compositions, and uses thereof
11/25/2010US20100297112 Combinations comprising dmxaa for the treatment of cancer
11/25/2010US20100297109 Methods for inhibiting fascin
11/25/2010US20100297107 Hmgb1 protein inhibitors and/or antagonists for the treatment of vascular diseases
11/25/2010US20100297105 Administering antisense oligonucleotides complementary to human apolipoprotein b
11/25/2010US20100297104 Dendritic macromolecule and a process thereof
11/25/2010US20100297102 Serotonin 5-ht3a receptors in treatment of neurological and psychiatric disorders
11/25/2010US20100297097 Compounds
11/25/2010US20100297095 Porifera-Based Therapeutic Compositions for Treating and Preventing Skin Diseases
11/25/2010US20100297091 Compositions and methods for treatment of melanomas
11/25/2010US20100297083 Polynucleotides and Polypeptide of Human KV1.3, Compositions Comprising Same and Methods of Using Same
11/25/2010US20100297082 Weight-bearing polyurethane composites and methods thereof
11/25/2010US20100297079 Compounds, compositions and methods for treating viral infection
11/25/2010US20100297077 Novel aryl potassium channel blockers and uses thereof
11/25/2010US20100297075 Combinational compositions and methods for treatment of cancer
11/25/2010US20100297074 Wound healing compositions, systems, and methods
11/25/2010US20100297073 Heterocyclic antiviral compounds
11/25/2010US20100297070 COMPOSITIONS AND METHODS FOR AMELIORATING CNS INFLAMMATION, PSYCHOSIS, DELIRIUM, PTSD or PTSS
11/25/2010US20100297060 Enhancement of antibody-cytokine fusion protein mediated immune responses by combined treatment with immunocytokine uptake enhancing agents
11/25/2010US20100297058 Prebiotic composition
11/25/2010US20100297056 Composition based on perhydrosqualene and collagen-polyvinylpyrrolidone for filling minor cutaneous depressions
11/25/2010US20100297054 1,2,3-triazole derivatives for use as stearoyl-coa desaturase inhibitors
11/25/2010US20100297051 Cosmetic composition comprising at least one elastomeric anionic polyurethane and at least one non-ionic thickener
11/25/2010US20100297050 Compositions containing silicone polymer, wax and volatile solvent
11/25/2010US20100297046 Compositions and Methods Related to Fructosamine-3-Kinase Inhibitors
11/25/2010US20100297041 Stable dispersions of solid particles in a hydrophobic solvent and methods of preparing the same
11/25/2010US20100297037 Material composition for oral hygiene product
11/25/2010US20100297035 Thiazole Amides, Imidazole Amides and Related Analogues
11/25/2010US20100297034 Osmolyte-containing preparation for use in case of dry mucous membranes
11/25/2010US20100297033 Megaribavirin alone or combination of other antiviral, antioxidant and a perflubron emulsion for treatment of viral disease
11/25/2010US20100297032 Transdermal delivery system
11/25/2010US20100297031 Orodispersible tablets
11/25/2010US20100297030 Composition, device, and method for treating sexual dysfunction via inhalation
11/25/2010US20100297029 Virucidal composition
11/25/2010US20100297028 Medicament combinations for the treatment of respiratory diseases
11/25/2010US20100297024 Promoter inducible by reactive oxygen species and vector comprising the same
11/25/2010US20100297023 Lipid
11/25/2010US20100297020 Phosphorylated and phosphonated pyrone analogs for therapeutic treatment
11/25/2010US20100297019 Particles for imaging
11/25/2010US20100297016 Quarternary nitrogen heterocyclic compounds for detecting aqueous monosaccharides in physiological fluids
11/25/2010US20100297015 Cancer biomarker and uses thereof
11/25/2010US20100297014 Method of detecting the risk of cancer using genetic markers
11/25/2010US20100297011 Isolated peptides and uses thereof
11/25/2010US20100297010 Tumor suppressor gene screening using rna interference libraries and method of treatment
11/25/2010US20100297008 Ganglioside associated recombinant antibodies and the use thereof in the diagnosis and treatment of tumors
11/25/2010US20100297007 Ligand directed toroidal nanoparticles for therapy and diagnostic imaging
11/25/2010US20100294686 Morpholino Compound Microemulsion
11/25/2010US20100294268 Aerosol Generating Method and Device
11/25/2010DE202010008608U1 Die pharmazeutische Zusammensetzung The pharmaceutical composition
1 ... 1989 1990 1991 1992 1993 1994 1995 1996 1997 1998 1999 2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 ... 7860